Sciele enjoys six-year stock high

After yesterday's news hit that Atlanta-based Sciele Pharma would accept Japan's Shionogi's generous buyout offer, shares of the drug company's stocks jumped nearly 60 percent.

The deal, for $31 per share, will net Sciele $1.4 billion. Shionogi's offer was 61 percent above the stock price at market closure on Friday, but the stock closed at almost the offer price, at $30.68 per share on Tuesday. 

Sciele's stocks haven't sold for over $30 since the beginning of 2002.

- see the story at Forbes.com
- find out what Business Week says

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.